Trop2-targeting drug for advanced neuroendocrine cancer
Part of Cancer clinical trials.
This trial tests a new medication that targets a protein on cancer cells, aiming to shrink tumors or slow their growth. It is for people with advanced neuroendocrine cancer that has not responded to earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a specific type of advanced neuroendocrine cancer that has spread or is high-grade.
- Your cancer must have grown after at least one previous round of treatment.
- You must be in good enough physical condition to perform daily activities (ECOG 0 or 1).
- You must have at least one tumor that can be measured and has not been previously treated with radiation.
- Your organ function (like liver, kidneys, blood counts) must be within certain limits.
- You must be willing to use effective contraception during and after the study, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a new combination of drugs (sacituzumab tirumotecan plus a third-generation EGFR inhibitor) with or without radiation therapy for advanced lung cancer that has spread to the brain after prior EGFR inhibitor treatment. The goal is to see if this combination can better control the cancer and improve outcomes for patients with brain metastases.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
This trial tests a new drug called Sac-TMT for people with advanced squamous cell carcinoma of the vagina or vulva that has spread or cannot be cured with standard treatments. The drug targets a protein on cancer cells to deliver chemotherapy directly to the tumor, potentially slowing or stopping its growth.
This trial uses a special PET scan to find a protein called Trop-2 on your cancer cells. It helps doctors decide if a targeted treatment (Trop-2 ADC) might work for you.
Hear when a new Neuroendocrine Neoplasms (Tumours) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.